XTLB
XTL Biopharmaceuticals Ltd ADR
NASDAQ: XTLB · HEALTHCARE · BIOTECHNOLOGY
$3.90
+9.55% today
Updated 2026-04-30
Market cap
$5.65M
P/E ratio
—
P/S ratio
5.84x
EPS (TTM)
$-3.60
Dividend yield
—
52W range
$2 – $10
Volume
2.3M
XTL Biopharmaceuticals Ltd ADR (XTLB) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-854.00%
ROE
-577.00%
ROA
-240.60%
Debt/equity
0.03x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2005 | $3.20M | $-14.02M | 12.51% | -449.80% | -438.38% |
| 2006 | $454000.00 | $-15.13M | 88.11% | -3,534.36% | -3,333.04% |
| 2007 | $907000.00 | $-24.94M | 87.87% | -2,837.38% | -2,749.61% |
| 2008 | $5.94M | $-9.25M | 100.00% | -161.46% | -155.66% |
| 2009 | — | $2.59M | — | — | — |
| 2010 | — | $-1.26M | — | — | — |
| 2011 | — | $-1.21M | — | — | — |
| 2012 | $938000.00 | $-1.39M | 59.49% | -251.17% | -148.19% |
| 2013 | $2.37M | $-2.48M | 68.72% | -122.16% | -104.52% |
| 2014 | $41000.00 | $-2.53M | -0.04% | -4,931.71% | -6,163.41% |
| 2015 | $-6000.00 | $-4.31M | 216.67% | 60,183.33% | 71,850.00% |
| 2016 | $23000.00 | $-2.54M | 86.96% | -11,134.78% | -11,065.22% |
| 2017 | $29000.00 | $-781000.00 | 96.55% | -4,296.55% | -2,693.10% |
| 2018 | $52000.00 | $2.99M | 100.00% | -1,525.00% | 5,742.31% |
| 2019 | $69000.00 | $-1.35M | 100.00% | -1,220.29% | -1,952.17% |
| 2020 | $28000.00 | $-782000.00 | -3.57% | -3,385.71% | -2,792.86% |
| 2021 | $1.47M | $435000.00 | -0.07% | -70.33% | 29.67% |
| 2022 | $-459000.00 | $-1.35M | 0.22% | 191.72% | 293.68% |
| 2023 | $0.00 | $-1782.00 | — | — | — |
| 2024 | $451000.00 | $-1.03M | 0.67% | -481.60% | -227.72% |